Actuate Therapeutics (ACTU) executive compensation, 2026 proxy

Daniel M. Schmitt, President and Chief Executive Officer, was paid $2.2M in 2025, down 61% from $5.6M the year before.

Filed
April 6, 2026
Annual meeting
May 21, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.2M-61% vs prior year
CEO 2025 Total Compensation
$2,166,522Decreased from prior year
CEO Base Salary
$570,000Effective January 1, 2025
CEO Option Awards
$1,454,193Grant date fair value
COO Total Compensation
$1,419,569For fiscal 2025
CFO Total Compensation
$1,006,361For fiscal 2025

How Schmitt was paid

$2.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary26%Bonus7%Option awards67%

Named executive officers

ExecutiveTotal
Daniel M. SchmittPresident and Chief Executive Officer$2,166,522
Andrew P. Mazar, Ph. D.Chief Operating Officer$1,419,569
Paul LytleChief Financial Officer$1,006,361

What changed and why

  • $5.6MCEO total compensation decreased from $5,578,616 in 2024 to $2,166,522 in 2025 following massive prior-year stock awards.
  • $570KBase salary for CEO Daniel M. Schmitt increased to $570,000 for fiscal 2025.
  • Executive compensation elements consisted of base salary, annual cash bonuses, and equity awards in stock options.
  • All stock options were granted under the 2024 Stock Incentive Plan with fair values determined using the Black-Scholes model.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.